Restriction site associated DNA sequencing for tumour mutation burden estimation and mutation signature analysis
Cancer Medicine · 2023
DOI: 10.1002/cam4.6711 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Conor F McGuinness und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Otago, Dunedin, New Zealand. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Breast Neoplasms. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: New Zealand Breast Cancer Foundation.
Abstract (Originalsprache)
Background
Genome‐wide measures of genetic disruption such as tumour mutation burden (TMB) and mutation signatures are emerging as useful biomarkers to stratify patients for treatment. Clinicians commonly use cancer gene panels for tumour mutation burden estimation, and whole genome sequencing is the gold standard for mutation signature analysis. However, the accuracy and cost associated with these assays limits their utility at scale.
Methods
WGS data from 560 breast cancer patients was used for in silico library simulations to evaluate the accuracy of an FDA approved cancer gene panel as well as restriction enzyme associated DNA sequencing (RADseq) libraries for TMB estimation and mutation signature analysis. We also transfected a mouse mammary cell line with APOBEC enzymes and sequenced resulting clones to evaluate the efficacy of RADseq in an experimental setting.
Results
RADseq had improved accuracy of TMB estimation and derivation of mutation profiles when compared to the FDA approved cancer panel. Using simulated immune checkpoint blockade (ICB) trials, we show that inaccurate TMB estimation leads to a reduction in power for deriving an optimal TMB cutoff to stratify patients for immune checkpoint blockade treatment. Additionally, prioritisation of APOBEC hypermutated tumours in these trials optimises TMB cutoff determination for breast cancer. The utility of RADseq in an experimental setting was also demonstrated, based on characterisation of an APOBEC mutation signature in an APOBEC3A transfected mouse cell line.
Conclusion
In conclusion, our work demonstrates that RADseq has the potential to be used as a cost‐effective, accurate solution for TMB estimation and mutation signature analysis by both clinicians and basic researchers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, University of Otago, Dunedin, New Zealand.
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
ORCID-Profile: Conor F McGuinness
Förderung
- New Zealand Breast Cancer Foundation
Zitieren
APA
McGuinness, C. F., Black, M. A., & Dunbier, A. K. (2023). Restriction site associated DNA sequencing for tumour mutation burden estimation and mutation signature analysis. Cancer Medicine. https://doi.org/10.1002/cam4.6711
Vancouver
McGuinness CF, Black MA, Dunbier AK. Restriction site associated DNA sequencing for tumour mutation burden estimation and mutation signature analysis. Cancer Medicine. 2023. doi:10.1002/cam4.6711
BibTeX
@article{McGuinness2023,
author = {McGuinness, Conor F and Black, Michael A and Dunbier, Anita K},
title = {Restriction site associated DNA sequencing for tumour mutation burden estimation and mutation signature analysis},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6711}
}
EUVIMED